Related Experiment Videos

Production of the modified form of human plasminogen by alpha 2-macroglobulin-plasmin complexes

Insights

Modified plasminogen, a key player in blood clot breakdown (fibrinolysis), is produced by alpha 2-macroglobulin-plasmin complexes. This supports its important role in the body.

Area of Science:

  • Biochemistry
  • Hematology
  • Proteolysis

Background:

  • The modified form of plasminogen is speculated to be crucial for fibrinolysis.
  • Plasminogen is a precursor to the proteolytic enzyme plasmin found in plasma.

Purpose of the Study:

  • To investigate the production of modified plasminogen by alpha 2-macroglobulin-plasmin complexes.
  • To understand the role of these complexes in plasminogen modification.

Main Methods:

  • Purification of alpha 2-macroglobulin-plasmin complexes from urokinase-activated plasma using affinity chromatography (lysine-Sepharose) and gel filtration (Ultrogel AcA 22).
  • Assessing the conversion of native plasminogen to its modified form in the presence of epsilon-aminocaproic acid.
  • Evaluating the inhibitory effects of aprotinin and soybean trypsin inhibitor on plasminogen modification.

Main Results:

  • Alpha 2-macroglobulin-bound plasmin efficiently converted native plasminogen into the modified form, especially with epsilon-aminocaproic acid.
  • Aprotinin completely inhibited this modification, while soybean trypsin inhibitor partially inhibited it.
  • Modified plasminogen was produced in human plasma, despite the presence of plasmin inhibitors, albeit to a lesser extent.

Conclusions:

  • The study supports the hypothesis that the modified form of plasminogen plays a significant role in in vivo fibrinolysis.
  • Alpha 2-macroglobulin-plasmin complexes are capable of producing modified plasminogen in a plasma environment.

Related Concept Videos